Immunic Inc (IMUX) Stock Price, Quote & News

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 255 9818

Website: imux.com

Address:

1200 Avenue of the Americas, Suite 200, New York, United States

Jw242 Jun. 24 at 4:28 PM

$IMUX I’ll break the silence. Good times!

2 · Reply

Cattitude Jun. 18 at 9:10 PM

$IMUX what was that 200k ah? 🤔

1 · Reply

Mattjen Jun. 18 at 11:22 AM

$IMUX

0 · Reply

Jw242 Jun. 17 at 3:37 PM

$IMUX laaars. We’re all just here for the buffet

2 · Reply

laaarsas Jun. 17 at 6:44 AM

$IMUX From what I can see there is no clinical data supporting the claim that targeting Nurr1 provides any extra benefit. Is the case for IMUX only a DHODH drug with less tox? How much could that be worth?

0 · Reply

laaarsas Jun. 16 at 8:26 PM

$IMUX What is actually expected here in terms of EFFICACY for the ENSURE program? For what endpoints?

0 · Reply

laaarsas Jun. 16 at 7:39 PM

$IMUX Their drug does not seem to work in progressive MS. Why should it work in relapsing MS?

1 · Reply

laaarsas Jun. 16 at 7:35 PM

$IMUX Is this homerun case or dogrun case?

0 · Reply

Jack8alot Jun. 16 at 2:05 PM

$IMUX youd think there would Be a little more interest. Still 1.38 afew months before readout. I was hoping for a buyout at $70 share. Back then. Doubt well see 700. But you never know

2 · Reply

Jw242 Jun. 15 at 3:12 PM

$IMUX always a bridesmaid on big up market days

1 · Reply

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Jun 1, 2026, 7:00 AM EDT - 23 days ago

Immunic Slides: Corporate presentation

May 29, 2026, 8:00 AM EDT - 26 days ago

Immunic Proxy statement: Proxy filing

May 28, 2026, 6:30 AM EDT - 27 days ago

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

2026-05-27T10:45:55.000Z - 4 weeks ago

Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed

May 27, 2026, 6:30 AM EDT - 4 weeks ago

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

2026-05-22T13:43:24.000Z - 4 weeks ago

B. Riley cuts Immunic target, sees ‘compelling entry point’

2026-05-19T10:35:10.000Z - 5 weeks ago

Immunic appoints Michael Bonney as chair

BIIB

May 19, 2026, 6:30 AM EDT - 5 weeks ago

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

2026-05-14T14:51:40.000Z - 5 weeks ago

Immunic price target lowered to $19 from $26 at Roth Capital

2026-05-13T11:25:48.000Z - 6 weeks ago

Immunic reports Q1 EPS ($1.08), consensus (96c)

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Immunic Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Immunic Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Immunic Slides: Investor presentation

May 13, 2026, 6:30 AM EDT - 6 weeks ago

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-04T11:36:42.000Z - 7 weeks ago

Immunic initiated with an Outperform at LifeSci Capital

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Immunic Registration statement: Registration filing

Apr 30, 2026, 6:30 AM EDT - 7 weeks ago

Immunic to Participate in Investor and Medical Conferences in May

2026-04-30T10:14:29.000Z - 7 weeks ago

Immunic price target adjusted to $22 from $5 at H.C. Wainwright

2026-04-28T11:19:28.000Z - 2 months ago

Immunic CMO Andreas Muehler to depart, Michael Panzara to succeed

Apr 28, 2026, 6:30 AM EDT - 2 months ago

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

2026-04-24T23:52:54.000Z - 2 months ago

Immunic trading halted, news pending

2026-04-23T12:08:47.000Z - 2 months ago

Immunic announces 1-for-10 reverse stock split

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

2026-04-16T20:20:56.000Z - 2 months ago

Immunic initiated with a Buy at Stifel

2026-04-15T11:24:13.000Z - 2 months ago

Immunic downgraded to Hold from Buy at D. Boral Capital

Apr 9, 2026, 6:30 AM EDT - 2 months ago

Immunic to Participate in Scientific and Medical Conferences in April

2026-04-02T20:35:15.000Z - 2 months ago

Immunic files to sell 458.15M shares of common stock for holders

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Immunic Registration statement: Registration filing

2026-04-01T10:40:28.000Z - 3 months ago

Immunic regains compliance with Nasdaq

Apr 1, 2026, 6:30 AM EDT - 3 months ago

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

2026-03-31T11:08:33.000Z - 3 months ago

Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board

MLYS

Mar 31, 2026, 6:30 AM EDT - 3 months ago

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

Mar 18, 2026, 12:00 PM EDT - 3 months ago

Immunic Transcript: Stifel 2026 Virtual CNS Forum

Mar 11, 2026, 10:40 AM EDT - 3 months ago

Immunic Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 6:30 AM EDT - 3 months ago

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Mar 3, 2026, 6:30 AM EST - 4 months ago

Immunic to Participate in Investor Conferences in March

Mar 2, 2026, 7:00 AM EST - 4 months ago

Immunic Proxy statement: Proxy Filing

Feb 26, 2026, 7:00 AM EST - 4 months ago

Immunic Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 4 months ago

Immunic Annual report: Q4 2025

Feb 26, 2026, 6:30 AM EST - 4 months ago

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Feb 20, 2026, 7:00 AM EST - 4 months ago

Immunic Proxy statement: Proxy Filing

Feb 17, 2026, 4:05 PM EST - 4 months ago

Immunic Announces Closing of Oversubscribed Private Placement Financing

Feb 13, 2026, 6:30 AM EST - 4 months ago

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Feb 4, 2026, 6:30 AM EST - 5 months ago

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Jan 7, 2026, 6:30 AM EST - 6 months ago

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Dec 4, 2025, 9:35 AM EST - 7 months ago

Immunic Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 26, 2025, 6:30 AM EST - 7 months ago

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Nov 13, 2025, 7:00 AM EST - 7 months ago

Immunic Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 7 months ago

Immunic Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 7 months ago

Immunic Slides: Company Presentation

Nov 13, 2025, 6:30 AM EST - 7 months ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 6:30 AM EDT - 8 months ago

Immunic to Participate in Industry and Investor Conferences in November

Oct 1, 2025, 6:30 AM EDT - 9 months ago

Immunic to Participate in Scientific and Investor Conferences in October

Sep 25, 2025, 6:30 AM EDT - 9 months ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 10 months ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 8, 2025, 7:00 AM EDT - 10 months ago

Immunic Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:00 AM EDT - 10 months ago

Immunic Slides: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 6:30 AM EDT - 10 months ago

Immunic to Participate in Investor and Scientific Conferences in September

Aug 7, 2025, 6:30 AM EDT - 11 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 6:30 AM EDT - 11 months ago

Immunic Quarterly report: Q2 2025

Aug 7, 2025, 6:30 AM EDT - 11 months ago

Immunic Earnings release: Q2 2025

Jun 24, 2025, 6:30 AM EDT - 1 year ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 5, 2025, 4:55 PM EDT - 1 year ago

Immunic Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 6:30 AM EDT - 1 year ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 3, 2025, 4:01 PM EDT - 1 year ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 2, 2025, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

May 29, 2025, 7:05 AM EDT - 1 year ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025, 4:02 PM EDT - 1 year ago

Immunic, Inc. Announces Proposed Public Offering

May 15, 2025, 12:00 AM EDT - 1 year ago

Immunic Quarterly report: Q1 2025

May 2, 2025, 6:30 AM EDT - 1 year ago

Immunic to Participate in Scientific and Industry Conferences in May

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Immunic Transcript: Study Update

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Immunic Press release: Study Update

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Immunic Slides: Study Update

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Immunic Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Immunic Proxy statement: Proxy Filing

Apr 10, 2025, 1:00 PM EDT - 1 year ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 1 year ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 1, 2025, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Mar 30, 2025, 6:00 PM EDT - 1 year ago

Immunic Annual report: Q4 2024

Mar 12, 2025, 10:00 AM EDT - 1 year ago

Immunic Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Scientific and Investor Conferences in March

Feb 26, 2025, 6:30 AM EST - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 20, 2025, 7:30 AM EST - 1 year ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 12, 2025, 1:20 PM EST - 1 year ago

Immunic Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 4, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in February

Jan 7, 2025, 6:30 AM EST - 1 year ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Dec 5, 2024, 11:30 AM EST - 1 year ago

Immunic Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunic Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunic Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunic Earnings release: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunic Slides: Q3 2024

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Sep 18, 2024, 3:05 PM EDT - 1 year ago

Immunic Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Jw242 Jun. 24 at 4:28 PM

$IMUX I’ll break the silence. Good times!

2 · Reply

Cattitude Jun. 18 at 9:10 PM

$IMUX what was that 200k ah? 🤔

1 · Reply

Mattjen Jun. 18 at 11:22 AM

$IMUX

0 · Reply

Jw242 Jun. 17 at 3:37 PM

$IMUX laaars. We’re all just here for the buffet

2 · Reply

laaarsas Jun. 17 at 6:44 AM

0 · Reply

laaarsas Jun. 16 at 8:26 PM

$IMUX What is actually expected here in terms of EFFICACY for the ENSURE program? For what endpoints?

0 · Reply

laaarsas Jun. 16 at 7:39 PM

$IMUX Their drug does not seem to work in progressive MS. Why should it work in relapsing MS?

1 · Reply

laaarsas Jun. 16 at 7:35 PM

$IMUX Is this homerun case or dogrun case?

0 · Reply

Jack8alot Jun. 16 at 2:05 PM

$IMUX youd think there would Be a little more interest. Still 1.38 afew months before readout. I was hoping for a buyout at $70 share. Back then. Doubt well see 700. But you never know

2 · Reply

Jw242 Jun. 15 at 3:12 PM

$IMUX always a bridesmaid on big up market days

1 · Reply

laaarsas Jun. 14 at 11:12 AM

$IMUX What is vibe like here?

1 · Reply

Jw242 Jun. 12 at 2:47 PM

$IMUX giddy up

1 · Reply

Mvvh1987 Jun. 12 at 12:52 PM

$IMUX if you see their recent vacancies I think they really are going to launch solo maybe with a partnership

1 · Reply

Jack8alot Jun. 11 at 9:58 PM

$IMUX better volume Should start seeing The. Moon. Soon

0 · Reply

AitorMenta Jun. 11 at 8:07 PM

$IMUX i am not very friends or charts but after RS we have very solid path. Bad news by the moment are solved, with coming good news, we are going to fly. Cash position very good and now we need good P3 data… Could be released any other drug update??? Celiac or similar?

1 · Reply

Jw242 Jun. 11 at 7:34 PM

$IMUX hmm

2 · Reply